Abstract
Objective To investigate the expressions of CCL25 and CCR9 in pancreatic cancer and tumor draining lymph nodes (TDLNs) , and to find out the relationship between the expressions of CCL25/CCR9 and the prognosis of pancreatic cancer. Methods 58 patients with pancreatic cancer and 10 patients with pancreatic benign diseases who received resectional surgery were studied from Jan 2006 to Jan 2008. Immunohistochemistry was used to detect the expressions of CCL25 and CCR9 in pancreatic cancer,TDLNs and benign diseases. Result Immunohistochemistry showed that the positive rate of CCR9 in TDLNs (86. 2%) was higher than in pancreatic cancer (79. 3%) (P<0. 05),which in turn was higher than benign diseases (40%) (P<0. 05). The positive rates of CCL25 in TDLNs, pancreatic cancer and benign diseases were 91.4% (53/58), 62.1% (36/58) , 40% (4/10),respectively. The expressions of CCL25/CCR9 protein in pancreatic cancer was associated with the clinical stage and the pathological type. There was significant difference in the survival time between the CCL25/CCR9 positive and negative patients (P<0. 05). Conclusions The expressions of CCL25/CCR9 were increased in pancreatic cancer and TDLNs, which suggested that CCL25/CCR9 might be involved in pancreatic cancer metastasis. CCL25/CCR9 might be regarded as an important marker in the prognosis. Key words: Pancreatic carcinoma; Immunohistochemistry; Survival rate
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
